Harvard doesn't have the HART for IPO
This article was originally published in Clinica
Executive Summary
After postponing its IPO plans last month, Harvard Bioscience has now altogether ditched the idea of floating its Harvard Apparatus Regenerative Technology (HART) subsidiary, citing poor market conditions. Instead, HART will now be spun-off to existing shareholders. Harvard initially announced plans for the IPO in March; it had been hoping to sell 1.7 million HART shares priced at $10-12 each to raise around $18.7 million (www.clinica.co.uk, 27 March 2013). However, it postponed the public offering in April (www.clinica.co.uk, 11 April 2013). HART makes synthetic organs for implantation from patients’ own stem cells, with an initial focus on the trachea. Its products are not yet approved anywhere in the world. The latest development is yet another indication of the sluggish IPO market, particularly in the US.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.